Reportlinker Adds Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, June 1, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Human Papillomavirus (HPV) Therapeutics market. The report identifies the key trends shaping and driving the global Human Papillomavirus (HPV) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Human Papillomavirus (HPV) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Human Papillomavirus (HPV) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Human Papillomavirus (HPV) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Human Papillomavirus (HPV) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Human Papillomavirus (HPV) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Human Papillomavirus (HPV) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Human Papillomavirus (HPV) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Human Papillomavirus (HPV) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Human Papillomavirus (HPV) Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 HPV Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Genital warts 7
2.1.2 Cervical cancer 8
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Signs and Symptoms 10
2.5 Diagnosis 10
2.5.1 Pap smear 10
2.5.2 Colposcopy 10
2.5.3 Biopsy 10
2.5.4 Human papillomavirus test 11
2.6 Treatment and Management Options 11
2.6.1 Genital Warts treatments 11
2.6.2 Cervical cancer treatments 12
2.7 GlobalData Pipeline Report Guidance 13
3 HPV Therapeutics - Market Characterization 14
3.1 HPV Therapeutics Market Size (2005-2010) – Global 14
3.2 HPV Therapeutics Market Forecast (2010-2017) – Global 15
3.3 HPV Therapeutics Market Size (2005–2010) – The US 16
3.4 HPV Therapeutics Market Forecast (2010-2017) – The US 17
3.5 HPV Therapeutics Market Size (2005–2010) – France 18
3.6 HPV Therapeutics Market Forecast (2010–2017) – France 19
3.7 HPV Therapeutics Market Size (2005–2010) – Germany 20
3.8 HPV Therapeutics Market Forecast (2010–2017) – Germany 21
3.9 HPV Therapeutics Market Size (2005–2010) – Italy 22
3.10 HPV Therapeutics Market Forecast (2010-2017) – Italy 23
3.11 HPV Therapeutics Market Size (2005–2010) – Spain 24
3.12 HPV Therapeutics Market Forecast (2010–2017) – Spain 25
3.13 HPV Therapeutics Market Size (2005–2010) – The UK 26
3.14 HPV Therapeutics Market Forecast (2010–2017) – The UK 27
3.15 HPV Therapeutics Market Size (2005–2010) – Japan 28
3.16 HPV Therapeutics Market Forecast (2010-2017) – Japan 29
3.17 Drivers and Barriers for the HPV Therapeutics Market 30
3.17.1 Barriers for the HPV Therapeutics Market 30
3.18 Opportunity and Unmet Need Analysis 31
3.19 Key Takeaway 32
4 HPV Therapeutics - Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profiles for the Major Marketed Products in the HPV Therapeutics Market 35
4.3.1 Gardasil (HPV quadrivalent (type 6, 11, 16 and 18) vaccine recombinant) 35
4.3.2 Cervarix (human papillomavirus bivalent (type 16, 18) vaccine, recombinant) 36
4.3.3 Condylox (podofilox) 38
4.3.4 Aldara (imiquimod, 5%) 38
4.3.5 Veregen (sinecatechin) 40
4.3.6 Alferon N (interferon alfa-n3) 41
4.4 Newly Approved Drug 42
4.4.1 Zyclara (imiquimod, 3.75%) 42
5 HPV Therapeutics - Pipeline Assessment 44
5.1 Overview 44
5.2 Strategic Pipeline Assessment 44
5.3 HPV Therapeutics Pipeline – Pipeline by Phases of Development 44
5.3.1 HPV Therapeutics – Phase III Pipeline 45
5.3.2 HPV Therapeutics – Phase II Pipeline 45
5.3.3 HPV Therapeutics – Phase I Pipeline 45
5.3.4 HPV Market – Discovery and Pre-Clinical Pipeline 46
5.3.5 Technology Trends Analytic Framework 47
5.4 HPV Therapeutics Market – Clinical Pipeline by Mechanism of Action 48
5.5 HPV Therapeutics – Promising Drugs Under Clinical Development 49
5.6 Molecule Profile for Promising Drugs Under Clinical Development 49
5.6.1 V503 49
5.6.2 LMV-601 50
5.6.3 R3484 50
5.7 Key Takeaway 51
6 HPV Therapeutics - Clinical Trials Mapping 52
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 52
6.2 Clinical Trials by Phase 53
6.3 Clinical Trials by Trial Status 54
6.4 Prominent Sponsors 55
6.5 Top Companies Participating in HPV Therapeutics Clinical Trials 56
7 Strategic Assessment 57
7.1 Key Events Impacting the Future Market 57
7.2 HPV Therapeutics - Implications for Future Market Competition 58
8 HPV Therapeutics - Future Players 60
8.1 Introduction 60
8.2 Company Profiles 60
8.2.1 Merck & Co 60
8.2.2 Glaskosmithkline plc 65
8.2.3 F.Hoffmann-La Roche Ltd. 70
8.2.4 Inovio Pharmaceuticals,Inc 74
8.2.5 Lumavita AG 76
9 HPV Therapeutics - Licensing and Partnership Deals 77
10 HPV Therapeutics - Appendix 80
10.1 Market Definitions 80
10.2 Abbreviations 80
10.3 Research Methodology Methodology 81
10.3.1 Coverage 81
10.3.2 Secondary Research 82
10.3.3 Forecasting 82
10.3.4 Primary Research 85
10.3.5 Expert Panel Validation 85
10.4 Contact Us 85
10.5 Disclaimer 85
10.6 Bibliography 86
1.1 List of Tables
Table 1: Cervical Cancer Treatment by Stage of the Disease, 2010 12
Table 2: HPV Therapeutics Market, Global, Revenue ($m) 2005–2010 14
Table 3: HPV Therapeutics Market, Global, Forecast ($m), 2010–2017 15
Table 4: HPV Therapeutics Market, The US, Revenue ($m), 2005–2010 16
Table 5: HPV Therapeutics Market, The US, Forecasts ($m), 2010–2017 17
Table 6: HPV Therapeutics Market, France, Revenue ($m), 2005–2010 18
Table 7: HPV Therapeutics Market, France, Forecasts ($m), 2010–2017 19
Table 8: HPV Therapeutics Market, Germany, Revenue ($m), 2005–2010 20
Table 9: HPV Therapeutics Market, Germany, Forecasts ($m), 2010–2017 21
Table 10: HPV Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Table 11: HPV Therapeutics Market, Italy, Forecasts ($m), 2010–2017 23
Table 12: HPV Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Table 13: HPV Therapeutics Market, Spain, Forecasts ($m), 2010–2017 25
Table 14: HPV Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Table 15: HPV Therapeutics Market, The UK, Forecasts ($m) 2010–2017 27
Table 16: HPV Therapeutics Market, Japan, Revenue ($m), 2005–2010 28
Table 17: HPV Therapeutics Market, Japan, Forecasts ($m), 2010–2017 29
Table 18: Zyclara, Clinical Trial Details, Complete Clearance of External Genital Warts Within 16 Weeks of Treatment (%) 43
Table 19: Zyclara, Clinical Trial Details, Complete Clearance of External Genital Warts Within 16 Weeks of Treatment by Gender (%), Combined Study 43
Table 20: HPV Therapeutics Market, Phase III Clinical Pipeline, 2010 45
Table 21: HPV Therapeutics Market, Phase II Clinical Pipeline, 2010 45
Table 22: HPV Therapeutics Market, Phase I Clinical Pipeline, 2010 45
Table 23: HPV Therapeutics Market, Discovery and Pre-Clinical Pipeline, 2010 46
Table 24: HPV Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010 49
Table 25: HPV Therapeutics Market, Number of Clinical Trials by Country, 2010 52
Table 26: HPV Therapeutics Market, Number of Clinical Trials by Phase, 2010 53
Table 27: HPV Therapeutics Market, Number of Clinical Trials by Status, 2010 54
Table 28: HPV Therapeutics Market, Number of Prominent Sponsors, 2010 55
Table 29: HPV Therapeutics Market, Top Companies Participating in Therapeutics Clinical Trials, 2010 56
Table 30: Merck &Co Infectious Diseases, Pipeline, 2010 62
Table 31: Merck &Co, Inc – Deals 63
Table 32: GlaxoSmithKline Plc. – Infectious Diseases, Pipeline, 2010 66
Table 33: GlaxoSmithKline Plc. Deals, Alliances and Partnerships , 2010-2011 67
Table 34: F. Hoffmann-La Roche Ltd ,Infectious Disease Pipeline, 2010 71
Table 35: F. Hoffmann-La Roche Ltd Deals, Alliances and Partnerships , 2010-2011 72
Table 36: Inovio Pharmaceuticals –Infectious Disease, Pipeline, 2010 75
Table 37: Inovio Pharmaceuticals, Inc. – Deals 75
Table 38: Lumavita Infectious Disease Pipeline 76
Table 39: Lmavita AG-Deals 76
Table 40: HPV Therapeutics Market, Global, Deals, 2010 77
1.2 List of Figures
Figure 1: Pathophysiology of HPV 9
Figure 2: HPV Therapeutics Market, Global, Revenue ($m), 2005–2010 14
Figure 3: HPV Therapeutics Market, Global, Forecasts ($m), 2010–2017 15
Figure 4: HPV Therapeutics Market, The US, Revenue ($m), 2005–2010 16
Figure 5: HPV Therapeutics Market, The US, Forecasts ($m), 2010–2017 17
Figure 6: HPV Therapeutics Market, France, Revenue ($m), 2005–2010 18
Figure 7: HPV Therapeutics Market, France, Forecasts ($m), 2010–2017 19
Figure 8: HPV Therapeutics Market, Germany, Revenue ($m), 2005–2010 20
Figure 9: HPV Therapeutics Market, Germany, Forecast ($m), 2010–2017 21
Figure 10: HPV Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Figure 11: HPV Therapeutics Market, Italy, Forecast ($m), 2010–2017 23
Figure 12: HPV Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Figure 13: HPV Therapeutics Market, Spain, Forecast ($m), 2010–2017 25
Figure 14: HPV Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Figure 15: HPV Therapeutics Market, The UK, Forecasts ($m), 2010–2017 27
Figure 16: HPV Therapeutics Market, Japan, Revenue ($m), 2005–2010 28
Figure 17: HPV Therapeutics Market, Japan, Forecasts 2010–2017 29
Figure 18: Opportunity and Unmet Need in the HPV Prophylactic Market, 2010 31
Figure 19: Opportunity and Unmet Need in the HPV Therapeutic Market, 2010 32
Figure 20: HPV Prophylactics Market, Strategic Competitor Assessment, 2010 33
Figure 21: HPV Therapeutics Market, Strategic Competitor Assessment, 2010 34
Figure 22: Aldara Cream, Clinical Trial Details 39
Figure 23: HPV Therapeutics Market, Pipeline by Phase of Development, 2010 44
Figure 24: HPV Therapeutics Market, Technology Trends Analytics Framework, 2010 47
Figure 25: HPV Therapeutics Market, Technology Trends Analytics Framework, Description, 2010 47
Figure 26: HPV Therapeutics Market, Pipeline by Mechanism of Action (%), 2010 48
Figure 27: HPV Therapeutics Market, Number of Clinical Trials by Country, 2010 52
Figure 28: HPV Therapeutics Market, Clinical Trials by Phase (%), 2010 53
Figure 29: HPV Therapeutics Market, Clinical Trials by Status (%), 2010 54
Figure 30: HPV Therapeutics Market, Prominent Sponsors (%), 2010 55
Figure 31: HPV Therapeutics Market, Drivers and Restraints 2010 57
Figure 32: HPV Prophylactics Market, Implications for Future Market Competition, 2010 58
Figure 33: HPV Therapeutics Market, Implications for Future Market Competition, 2010 59
Figure 34: HPV Therapeutics Market, Pipeline by Company, 2010 60
Figure 35: GlobalData Market Forecasting Model 84
Companies Mentioned
Merck & Co
Glaskosmithkline plc
F.Hoffmann-La Roche Ltd.
Inovio Pharmaceuticals,Inc
Lumavita AG
To order this report:
Drug Discovery and Development Industry: Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Drug Discovery and Development Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article